Key facts
- VerAvanti’s last known valuation is $161.0M (Oct 2025).
- It has raised $43.4M across 2 recorded rounds; the latest was Early Stage VC ($28.3M) in Feb 2025.
- Notable investors include Lung, National Cancer Institute, National Heart, UW CoMotion, University of Washington — 6 tracked in total.
- VerAvanti has filed 2 Form Ds with the SEC since 2017, most recently Mar 2025 ($28.3M sold to 17 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for VerAvanti
Funding rounds
2 roundsAbout VerAvanti
Developer of a scanning fiber endoscope device designed to identify the causes of strokes and cardiac events. The company's device consists of an imaging station and a tiny catheter that is designed to take high-definition images, enabling doctors and surgeons to have a peek into hidden intravascular anatomy and visually identify potential risks for stroke and cardiovascular risks.
- Sector
- Healthcare
- HQ
- Bothell, WA, United States
- Founded
- 2013
- Employees
- 18
- Website
- veravanti.com/
- Ownership
- Privately Held (backing)
VerAvanti doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in VerAvanti shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on VerAvanti in its N-PORT filings yet. We sweep new filings monthly.